Semaglutide

Na Disemba 2017, US Food and Drug Administration (FDA) kwadoro ndepụta nke Smeglugan peptide injection na njikwa nri inyeaka na mmega ahụ iji meziwanye njikwa glucose ọbara nke ndị ọrịa nwere ụdị ọrịa shuga 2.Na mgbakwunye, Novo na Nord zụlitekwara ụdị ọgwụgwọ ọnụ Rybelsus nke Smeglugin, FDA kwadoro ya na Septemba 2019. Nke a bụkwa ọgwụ GLP-1 nke mbụ kwadoro n'ụwa.ọrịa shuga mellitus.N'ezie, Smeglugin bụ ọgwụ hypoglycemic, mana n'ihi na ọgwụ ndị dị ka Smeglugin peptide nwere ike belata afọ efu ma gbochie agụụ, ọ ga-ebelata ibu.

N'ihi nke a, na June 2021, FDA kwadoro njikwa ịdị arọ ogologo oge nke oke ibu ma ọ bụ ndị okenye buru ibu.Ndị ọdabara bụ: ndị ọrịa dị mfe nwere BMI ≥30 kg/m2;na BMI> 27 n'arọ / m2 wee jikọta opekata mpe otu mgbagwoju anya oke ibu, dị ka ọbara mgbali elu, ụdị ọrịa shuga 2, ma ọ bụ lipids ọbara na-adịghị mma.Ọ bụkwa nkwenye a ka e liri ihe atụ ahụ maka Smeglugin n'okporo ụzọ "ọgwụ anwansi ọnwụ".

N'April 2021, akwadoro Smegugan na China maka njikwa shuga ọbara maka ndị ọrịa nwere ụdị ọrịa shuga 2 (T2DM).Ọ bụ ezie na akwadoghị ihe ngosi ịdị arọ nke ịdị arọ na China, a pụghị ijide ọchịchọ maka ọnwụ anụ ụlọ na China.Na mgbakwunye, isi isiokwu nke "mkpa na mkpa", na ọkara nke abụọ nke 2022, Smeglugin peptide "anabataghị" na ubi nke ibu ibu., N'otu oge na otutu e-azụmahịa nyiwe, ọ esetịpụ a ọganihu na ịzụrụ, na ozugbo ghọrọ a elu -priced "esi na ngwaahịa eze", nke butere ozugbo na nsogbu nke emepụta' mmepụta na ọkọnọ.Nuo na Nord nke Julaị afọ gara aga kwuru na ịmaliteghachi inye ọgwụ ga-akwụsị ịnye ahịa ahịa ụlọ ọgwụ.

Ekwuputakwara na ọ bụ Smegugu peptide na-ewu ewu site na data ego nke Nuo na Nord.Dabere na nsonaazụ 2022 na nso nso a nke Nuo na Nord kwuputara, ego a na-enweta kwa afọ nke Nuo na Nord's GLP-1 azụmahịa bụ ijeri 83.371 Dan Ying Crown (nke ihe dị ka ijeri yuan 81.6), mmụba nke 56% kwa afọ.N'ime ha, ahịa Smeglugin bụ ijeri 59.75 Dan Ying Crown (ihe dị ka ijeri yuan 58.5), mmụba nke 77% afọ na afọ.Ọrụ ahịa nke ngwaahịa GLP-1 n'ọhịa ụdị ọgwụgwọ ọrịa shuga 2 na China abawanyela site na 102% na Dan Ying Krone.

N'ezie, mgbawa nke Smeglugin n'ọhịa nke ibu ibu nwere njikọ chiri anya na mmetụta ya dị ịrịba ama."Ọ bụ oge iri ihe, ịṅụ ihe ọṅụṅụ na ịṅụ ihe ọṅụṅụ, were 5 pound nke arọ, hapụ 30 pound na January" na ihe ndị ọzọ.Na mgbakwunye, "ịgha ụgha" nwere ike ịdị gịrịgịrị, nke dọtara ọtụtụ anya na Smegtu peptides, nke a na-akpọbu "ọgwụ anwansi ibu ibu".Agbanyeghị, ụfọdụ ndị dọkịta ekwuola na Simei Gulu peptide nwere ihe karịrị 2/3 nke ahịa ụlọ na China iji felata, ọ bụghị ọrịa shuga.N'otu aka ahụ N'ihe gbasara Smeglugan peptide dị ka ọgwụ ndenye ọgwụ, enwere ihe egwu zoro ezo na nchekwa nke ọgwụ ndị na-arịa ọrịa shuga.

Ọ dị mma ịmara na nkwubi okwu nyocha ụlọ nke ọgwụ ndị dị otú ahụ sitere n'aka ndị ọrịa buru ibu buru ibu.Maka ndị nwere ntakịrị abụba ma ọ bụ ọbụna ịdị arọ nkịtị (BM <27kg/m2), a ka amabeghị uru na ihe egwu nwere ike ime.Na mgbakwunye, na mgbakwunye na mmeghachi omume hypoglycemia bụ ọgwụ hypogenal nke na-eme na ọgwụ hypoglycemic, mmeghachi omume eriri afọ na-apụta ìhè, na ọgbụgbọ, afọ ntachi, vomiting na afọ ọsịsa ruru 82.8%.7%Ihe kachasị mkpa bụ na akwadobeghị Smeglugin maka ihe ngosi mbelata ibu na China.Nsogbu nke ọwa ọgwụ na iji ọgwụ ọjọọ eme ihe nke ndị dị otú ahụ kwesịrị nlebara anya.